Sign In
Buy QGEN
$41.40
-0.0500 (-0.121%)
At Close: Jul 31, 2026
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
04:05pm, Tuesday, 29'th Jun 2021
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #forensics--QIAGEN partners with Verogen to offer broadest portfolio for human identification, including next generation sequencing solutio
Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments
06:45am, Tuesday, 22'nd Jun 2021
Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiag
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
04:05pm, Monday, 21'st Jun 2021
HILDEN, Germany, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #CRISPR--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS
03:02pm, Tuesday, 01'st Jun 2021
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #fda--QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours
QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm
06:46am, Thursday, 27'th May 2021
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test
10:31am, Tuesday, 18'th May 2021
QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
06:15am, Monday, 17'th May 2021
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces creation of Scientific Advisory Board and agenda for Annual General Meeting in June 2021
QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA
10:32am, Friday, 14'th May 2021
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
QIAGEN's (QGEN) CEO Thierry Bernard on Q1 2021 Results - Earnings Call Transcript
01:28am, Wednesday, 05'th May 2021
QIAGEN's (QGEN) CEO Thierry Bernard on Q1 2021 Results - Earnings Call Transcript
QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up
09:02am, Tuesday, 04'th May 2021
QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.
Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues
07:10am, Tuesday, 04'th May 2021
Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million. Adjusted E
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
06:49pm, Monday, 03'rd May 2021
Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Qiagen reports first-quarter beat thanks to growth in non-COVID-19 products
04:30pm, Monday, 03'rd May 2021
U.S.-German genetic testing specialist Qiagen reported slightly better-than-expected quarterly earnings on Monday as sales growth for non-coronavirus products added to high demand for its COVID-19 tes
HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN with DiaSorin, announce the launch of LIAISON® LymeDetect® Assay based on QuantiFERON technology for early diagnosis of Lyme Borreliosis
